Market Analysis · 01
How the premium IOL market is shifting from maximum range to better quality of vision
A post-ESCRS view of the premium IOL landscape: visual range, quality of vision and the practical constraints that shape adoption. Clinical evidence, manufacturer statements and strategic interpretation remain distinct.
Read opens the full PDF in a new tab.
The market analysis in one minute
Clinical evidence
Near vision favours trifocals in the cited synthesis; lack of a detected difference on other endpoints does not establish equivalence.
Review p. 03 · references R2–R3Technology
This is the report’s strategic interpretation, not a product ranking or a synthetic head-to-head comparison.
Review pp. 04–05Adoption
The adoption framework is OIE interpretation, not a validated clinical score. Adjustability addresses a different problem from trifocality.
Review pp. 06–09The definitive full market analysis
Complete evidence, methods and references are in the PDF.
If your browser does not display the reader, open the PDF directly.
These declarations concern OIE and its author. They do not describe the funding or financial relationships of the studies reviewed.
Evidence appraised through 21 September 2026. Version 1.1. Later findings may change interpretation.